| | | This week was generally positive for biotechs, and for most of the contest portfolios. The NASDAQ composite was ahead by +0.3% for the week, a fairly anemic addition to the YTD value of +16%. The biotech indices were stronger. The NASDAQ biotech index up +0.6%, moved into positive territory, YTD. The S&P biotech index had an even better week, +1.6%, but it will take another four weeks of such returns to take it out of the red, YTD.
OMER was the best performing stock for the week, +69%, perhaps because of a recent award of a $6.7 million grant from the National Instituted of Drug Addiction (NIDA, a component of the NIH), for further studies with their treatment for cocaine addiction. This weeks gain builds on a general upward trend for the year, moving from 5th place YTD to 4th, +181%.
Second and third place winners for the week, CRIS (+61%) and EYEN (+58%), showed steady growth through the week for no particular reason available through the Yahoo! Finance news feed. EYEN’s weekly performance also moved it from 4th to 3rd YTD.
The biggest loser for the week was RVNC, off -20%, again for no clear particular reason. It still is in the black YTD, +65%, though.
This was a significantly better week for the contest portfolios, adding +$3.1k average and +$3.2k median for the week, in contrast to last weeks average haircut of -$1k to the average, and a lackluster +$157 for the median portfolio. All but four of the portfolios were in the black, (and two of those had bet big on RVNC).
The best performing portfolio for the week was picked by ARTHUR RADLY, +$14.3k, almost double STEVE LOKNESS in second, $7.3k. ARTHUR RADLY’s performance was thanks to a 20% bet on EYEN (third best performer for the week). EYEN is also the big YTD performer in their portfolio, moving them from fifth to third place with +$35k.
In contrast to BLADERUNNER’s disappointing last week, they were in third place for the week, +$7.1k, thanks to earning +$9.1k with CRIS, even with another week of red ink for JSPR (only -$830 though, instead of last week's drop of -$14.1k). But BLADERUNNER’s hold on the number one position YTD, (+$46.1 k) was only slightly improved (now a margin of +$2.8k vs. their margin of +$2.7k last week) because YTD second place ALONER also had a position in CRIS, and their weekly performance was just behind BLADERUNNER's, earning $6.9k with the fourth place portfolio for the week.
Report Time Ranges
|
|
|
|
|
|
From
|
To
|
|
|
|
|
|
|
|
|
Recent
|
4/7/23
|
4/14/23
|
|
|
|
|
|
|
|
|
YTD
|
12/31/2022
|
|
|
|
|
Index Portfolios’ Performance
|
|
|
|
|
Symbol
|
Recent P/L
|
Recent %
|
YTD P/L
|
|
|
|
|
|
|
|
|
^IXIC
|
$339.27
|
0.3%
|
$15,831.35
|
|
|
|
|
|
|
|
|
^NBI
|
$579.30
|
0.6%
|
$118.50
|
|
|
|
|
|
|
|
|
^SPSIBI
|
$1,461.99
|
1.6%
|
-$6,880.32
|
|
|
|
|
Share Performance
|
Recent Performance
|
YTD Performance
|
|
Top Five
|
|
Bottom Five
|
|
Top Five
|
|
Bottom 5
|
Symbol
|
P/L / Initial Price
|
Symbol
|
P/L / Initial Price
|
Symbol
|
YTD P/L / Initial Price
|
Symbol
|
YTD P/L/ Initial Price
|
OMER
|
69.0%
|
RVNC
|
-19.6%
|
INZY
|
429.5%
|
ALT
|
-70.9%
|
CRIS
|
60.9%
|
CDTX
|
-15.9%
|
JSPR
|
200.2%
|
FULC
|
-66.9%
|
EYEN
|
57.7%
|
ICVX
|
-14.9%
|
EYEN
|
185.3%
|
BLCM
|
-61.0%
|
TGTX
|
40.9%
|
CLSD
|
-12.5%
|
OMER
|
181.0%
|
BCAB
|
-56.4%
|
ICPT
|
32.6%
|
MODD
|
-12.5%
|
PRVB
|
130.4%
|
GLYC
|
-51.5%
|
Average and Median Portfolio Performance
|
|
Recent P/L
|
|
|
|
YTD P/L
|
|
|
|
Avg.
|
Median
|
|
|
|
Avg
|
Median
|
|
|
|
$3,077.91
|
$3,157.91
|
A.J. MULLEN
|
|
$10,378.51
|
$6,515.00
|
BULBAMAN
|
Top Seven Portfolio Performances
|
Top Recent Performers
|
Top YTD Performers
|
Contestant (Prev. Rank)
|
Recent P/L
|
P/L vs. ^SPSIBI
|
YTD P/L (Rank)
|
Contestant (Prev. Rank)
|
YTD P/L
|
vs. Top Portfolio
|
P/L vs. ^SPSIBI
|
Rec. P/L (Rank)
|
1 - ARTHUR RADLEY (7)
|
$14,321.90
|
$12,859.91
|
$35,343.62 (3)
|
1 - BLADERUNNER (1)
|
$46,057.55
|
——
|
$52,937.88
|
$7,082.66 (3)
|
2 - STEVE LOKNESS (14)
|
$7,270.20
|
$5,808.21
|
$23,893.69 (6)
|
2 - ALONER (2)
|
$43,247.52
|
$2,810.03
|
$50,127.85
|
$6,937.80 (4)
|
3 - BLADERUNNER (15)
|
$7,082.66
|
$5,620.68
|
$46,057.55 (1)
|
3 - ARTHUR RADLEY (5)
|
$35,343.62
|
$10,713.93
|
$42,223.94
|
$14,321.90 (1)
|
4 - ALONER (5)
|
$6,937.80
|
$5,475.82
|
$43,247.52 (2)
|
4 - TOMATO (3)
|
$27,995.93
|
$18,061.62
|
$34,876.25
|
-$3,469.37 (13)
|
5 - BULBAMAN (4)
|
$5,847.96
|
$4,385.97
|
$6,515.00 (8)
|
5 - RKRW (4)
|
$27,160.92
|
$18,896.63
|
$34,041.25
|
$2,846.85 (9)
|
6 - BMAZ001 (10)
|
$5,542.24
|
$4,080.26
|
-$29,009.75 (15)
|
6 - STEVE LOKNESS (6)
|
$23,893.69
|
$22,163.87
|
$30,774.01
|
$7,270.20 (2)
|
7 - RAJU_BIJLEE (13)
|
$3,548.73
|
$2,086.74
|
-$22,844.05 (14)
|
7 - TECHNETIUM (7)
|
$8,499.92
|
$37,557.63
|
$15,380.25
|
-$3,490.21 (14)
|
Top Portfolios’ Contents
|
Top Recent Performance Portfolio (ARTHUR RADLEY)
|
Top YTD Performance Portfolio (BLADERUNNER)
|
Symbol (Rank)
|
Current Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
ABCM
|
10.0%
|
7.4% | 0.3%
|
$25.71
|
$1,793.06
|
10.0%
|
CRDF
|
20.0%
|
14.6% | 6.4%
|
$1,285.71
|
-$71.43
|
4.7%
|
AKYA
|
10.0%
|
5.4% | -26.4%
|
-$2,643.68
|
-$94.04
|
13.6%
|
CRIS
|
15.0%
|
17.6% | 71.8%
|
$10,772.73
|
$9,136.36
|
3.9%
|
ALVR
|
10.0%
|
5.6% | -24.4%
|
-$2,436.65
|
$155.95
|
13.2%
|
ENTA
|
5.0%
|
2.7% | -21.5%
|
-$1,073.73
|
-$356.84
|
25.5%
|
ASRT
|
10.0%
|
10.8% | 46.3%
|
$4,627.91
|
$372.09
|
6.8%
|
IOVA
|
10.0%
|
6.0% | -11.7%
|
-$1,173.71
|
-$453.83
|
11.3%
|
EYEN
|
20.0%
|
42.2% | 185.3%
|
$37,055.21
|
$11,533.74
|
1.8%
|
JSPR
|
20.0%
|
41.1% | 200.2%
|
$40,041.41
|
-$828.16
|
1.7%
|
IDIA.SW
|
20.0%
|
11.0% | -25.6%
|
-$5,110.58
|
-$24.43
|
6.7%
|
MBIO
|
10.0%
|
3.9% | -42.8%
|
-$4,278.48
|
$50.63
|
17.5%
|
ISEE
|
10.0%
|
9.8% | 32.1%
|
$3,213.45
|
$569.83
|
7.6%
|
MGTA
|
5.0%
|
6.8% | 97.2%
|
$4,860.76
|
$450.63
|
10.1%
|
LQDA
|
10.0%
|
7.8% | 6.1%
|
$612.24
|
$15.70
|
9.4%
|
MRSN
|
15.0%
|
7.3% | -29.2%
|
-$4,377.13
|
-$844.71
|
9.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
